Freeox Biotech is a pioneering company in the field of neuroprotection, focusing on developing therapies to mitigate the damage caused by ischemia, particularly in stroke patients. The company operates in the biopharmaceutical sector, targeting healthcare providers and medical institutions that treat neurological conditions. Freeox Biotech's business model revolves around the research, development, and commercialization of innovative medicinal products. Their primary products include Ox 01, a uric acid-based treatment, and Ox 02 Uricoline, a combination of uric acid and Citicoline. These products are designed to prevent damage caused by reperfusion after a stroke, thereby improving patient recovery outcomes. The company generates revenue through the sale of these medicinal products to hospitals and clinics, as well as through partnerships and licensing agreements with larger pharmaceutical companies. Freeox Biotech's market is primarily focused on regions with high incidences of stroke and ischemic conditions, making their products highly relevant and in demand.

Keywords: neuroprotection, ischemia, stroke recovery, uric acid, Citicoline, reperfusion, biopharmaceutical, medicinal products, healthcare providers, neurological conditions.